页 1 从 33 结果
FIELD OF THE INVENTION
The present invention relates to pharmaceutical compositions and methods of using these compositions to treat patients for tobacco addiction and nicotine addiction, to palliate the effects of nicotine withdrawal and to enhance the outcomes of other smoking cessation therapies.
The present invention relates to a cytokine for use in the treatment and/or control of dependent and/or addictive behavior, in particular addiction and/or dependency to nicotine, food addiction, alcohol addiction and/or sex addiction. The present invention also relates to treatment and/or control of
FIELD OF THE INVENTION
The present invention relates generally to a method for decreasing human's cravings for cigarettes and reducing instances of relapse during detoxification once smoking abstinence has been achieved, and more specifically, to a method for decreasing nicotine use by treating a
FIELD OF THE INVENTION
The present invention relates generally to a method for decreasing human's cravings for cigarettes and reducing instances of relapse during detoxification once smoking abstinence has been achieved, and more specifically, to a method for decreasing nicotine use by treating a
FIELD OF THE INVENTION
This invention relates to chain-modified analogs of N-n-octylnicotinium iodide (NONI) and N-n-decylnicotinium iodide (NDNI) that have selective .alpha..sub.3.beta..sub.2* and .alpha..sub.4.beta..sub.2 nicotinic receptor antagonist properties respectively, and to a method of
Obesity is a life-threatening disorder in which there is an increased risk of morbidity and mortality arising from concomitant diseases such as type II diabetes, hypertension, stroke, cancer, and gallbladder disease.
Obesity is now a major healthcare issue in the Western World and increasingly in
Obesity is a life-threatening disorder in which there is an increased risk of morbidity and mortality arising from concomitant diseases such as type II diabetes, hypertension, stroke, cancer, and gallbladder disease.
Obesity is now a major healthcare issue in the Western World and increasingly in
Obesity is a life-threatening disorder in which there is an increased risk of morbidity and mortality arising from concomitant diseases such as type II diabetes, hypertension, stroke, cancer, and gallbladder disease.
Obesity is now a major healthcare issue in the Western World and increasingly in
TECHNICAL FIELD
Embodiments disclosed herein generally relate to a method of treatment for weight-loss and other conditions in a mammal. More particularly, embodiments herein are directed to anatomically targeted, low-dosage delivery of antiepileptic/anticonvulsant compounds for weight-loss and
FIELD OF THE INVENTION
The present invention relates to the use of pramipexole or 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or the (-)-enantiomers thereof, and the pharmacologically acceptable salts thereof, for the treatment of several nervous system disorders, including: Addictive
FIELD OF THE INVENTION
This invention describes new treatments for several nervous system disorders, including: Addictive Disorders, Psychoactive Substance Use Disorders, Nicotine Addiction or Tobacco Addiction resulting in Smoking Cessation and Attention Deficit Hyperactivity Disorder (ADHD). The
FIELD OF THE INVENTION
This invention describes new treatments for several nervous system disorders, including: Addictive Disorders, Psychoactive Substance Use Disorders, Nicotine Addiction or Tobacco Addiction resulting in Smoking Cessation and Attention Deficit Hyperactivity Disorder (ADHD). The
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to the use of neuromuscular agents, and the pharmacologically acceptable salts thereof, for the treatment of, or improving symptoms of, several nervous system disorders. More particularly, the invention relates to treatment
TECHNICAL FIELD
The present invention relates to pharmaceutically active compositions consisting of 4',4''-substituted 3.alpha.-(diphenylmethoxy) tropane analogs which are used in a method for treating specific psychiatric disorders including narcolepsy, attention deficit hyperactivity disorder
FIELD OF THE INVENTION
The present invention relates to acylated spiropiperidine derivatives, their synthesis, and their use as melanocortin receptor (MC-R) ligands useful to modulate bodyweight. More particularly, the compounds of the present invention are ligands of the melanocortin-4 receptor